Hiltonol

Generic Name: Hiltonol

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 59789-29-6

Unique Ingredient Identifier: 7KYP9TKT70

Associated Conditions: -

Associated Therapies: -

Clinical Trials

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Biological: PGV-001
Biological: Poly-ICLC
Biological: CDX-301

First Posted Date: 2021-08-18

Last Posted Date: 2024-10-28

Lead Sponsor: Ashutosh Kumar Tewari

Target Recruit Count: 27

Registration Number: NCT05010200

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, United States

In Situ Immunomodulation with CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients W/ Unresectable and Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Unresectable Melanoma
Cutaneous Squamous Cell Carcinoma
Merkel Cell Carcinoma
Soft Tissue Sarcoma
Bone Sarcoma
Sarcoma,Soft Tissue
Anatomic Stage IV Breast Cancer AJCC V8
Metastatic Breast Carcinoma
Prognostic Stage IV Breast Cancer AJCC V8
Unresectable Breast Carcinoma

Interventions: Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140
Drug: Poly ICLC
Radiation: Radiation Therapy
Biological: Recombinant Flt3 Ligand
Drug: Pembrolizumab
Drug: Tocilizumab

First Posted Date: 2020-11-04

Last Posted Date: 2024-12-16

Lead Sponsor: University of Southern California

Target Recruit Count: 18

Registration Number: NCT04616248

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

A Phase II Trial of Poly-ICLC for Low-Grade Gliomas

Phase 2

Recruiting

Conditions: NF1
Low-grade Glioma

Interventions: Drug: Poly ICLC

First Posted Date: 2020-09-10

Last Posted Date: 2024-03-15

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 20

Registration Number: NCT04544007

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
The University of Alabama at Birmingham (Site 700), Birmingham, Alabama, United States
🇺🇸
Children's Lurie Hospital, Chicago, Illinois, United States

and more 9 locations

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Phase 1

Recruiting

Conditions: Recurrent Glioblastoma

Interventions: Biological: Dendritic Cell Tumor Cell Lysate Vaccine
Other: Placebo Administration
Biological: Pembrolizumab
Drug: Poly ICLC

First Posted Date: 2019-12-17

Last Posted Date: 2024-10-16

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT04201873

Locations: 🇺🇸
Quan, Los Angeles, California, United States

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Breast Cancer
Merkel Cell Carcinoma
Non Small Cell Lung Cancer
Ovarian Cancer
Hepatocellular Carcinoma
Melanoma
Microsatellite Instability High
Cervical Cancer
Small-cell Lung Cancer
Squamous Cell Cancer

Interventions: Device: Echopulse
Drug: Standard of Care PD-1 Therapy
Drug: Poly ICLC

First Posted Date: 2019-10-04

Last Posted Date: 2023-08-07

Lead Sponsor: Craig L Slingluff, Jr

Target Recruit Count: 5

Registration Number: NCT04116320

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Phase 1

Terminated

Conditions: Pancreas Cancer
Pancreatic Cancer
Cancer of the Pancreas

Interventions: Biological: Neoantigen Peptide Vaccine
Drug: Poly ICLC
Procedure: Blood for immune monitoring

First Posted Date: 2019-05-20

Last Posted Date: 2024-07-17

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 12

Registration Number: NCT03956056

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Vaccination With Flt3L, Radiation, and Poly-ICLC

Phase 1

Recruiting

Conditions: Non-Hodgkin's Lymphoma
Metastatic Breast Cancer
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Flt3L
Radiation: Radiation
Drug: Poly ICLC

First Posted Date: 2018-12-28

Last Posted Date: 2024-01-30

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 56

Registration Number: NCT03789097

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Invasive Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Biological: Durvalumab
Drug: Gemcitabine Hydrochloride
Procedure: Magnetic Resonance Imaging
Drug: Nab-paclitaxel
Biological: Personalized Synthetic Long Peptide Vaccine
Drug: Poly ICLC
Biological: Sacituzumab Govitecan
Biological: Tremelimumab

First Posted Date: 2018-07-31

Last Posted Date: 2024-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT03606967

Locations: 🇺🇸
Moffitt Cancer Center at Wesley Chapel, Wesley Chapel, Florida, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 27 locations

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Blasts 30 Percent or Less of Bone Marrow Nucleated Cells
Chronic Myelomonocytic Leukemia
High Risk Myelodysplastic Syndrome
Myelodysplastic Syndrome
Refractory Anemia

Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Drug: Poly ICLC

First Posted Date: 2017-12-02

Last Posted Date: 2021-10-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT03358719

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

Phase 1

Completed

Conditions: Urothelial/Bladder Cancer, Nos

Interventions: Drug: Atezolizumab
Biological: PGV001
Drug: Poly ICLC
Drug: Normal saline

First Posted Date: 2017-12-02

Last Posted Date: 2023-05-16

Lead Sponsor: Matthew Galsky

Target Recruit Count: 10

Registration Number: NCT03359239

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy